CRDF
Cardiff Oncology Inc
NASDAQ: CRDF · HEALTHCARE · BIOTECHNOLOGY
$1.73
+6.79% today
Updated 2026-04-30
Market cap
$117.60M
P/E ratio
—
P/S ratio
198.31x
EPS (TTM)
$-0.69
Dividend yield
—
52W range
$1 – $5
Volume
0.7M
WallStSmart proprietary scores
31
out of 100
Grade: F
Strong Sell
Investment rating
7.3
Growth
B+6.5
Quality
B2.5
Profitability
F6.7
Valuation
B2/9
Piotroski F-Score
Weak
-2.6
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →200 stocks currently score above 75
Price targets
Analyst target
$7.75
+347.98%
12-Month target
—
—
Intrinsic (DCF)
$4.95
Margin of safety
+67.68%
1 Strong Buy6 Buy1 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ Revenue growth 60.90% QoQ
+ 67.68% below intrinsic value
+ Debt/equity 0.02x — low leverage
Risks
- Piotroski 2/9 — weak financial health
- Altman Z -2.58 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-5.97M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $386000.00 | $488000.00 | $683000.00 | $593000.00 | $593000.00 |
| Net income | $-38.70M | $-41.44M | $-45.43M | $-45.88M | $-7.22M |
| EPS | — | — | — | — | $-0.69 |
| Free cash flow | $-34.71M | $-31.47M | $-37.77M | $-37.97M | $-5.97M |
| Profit margin | -10,026.94% | -8,492.01% | -6,651.68% | -7,736.26% | — |
Peer comparison
Smart narrative
Cardiff Oncology Inc trades at $1.73. Our Smart Value Score of 31/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of -2.58, it sits in the distress. TTM revenue stands at $593000.00. Our DCF model estimates intrinsic value at $4.95.
Frequently asked questions
What is Cardiff Oncology Inc's stock price?
Cardiff Oncology Inc (CRDF) trades at $1.73.
Is Cardiff Oncology Inc overvalued?
Smart Value Score 31/100 (Grade F, Strong Sell). DCF value $4.95.
What is the price target of Cardiff Oncology Inc (CRDF)?
The analyst target price is $7.75, representing +348.0% upside from the current price of $1.73.
What is the intrinsic value of Cardiff Oncology Inc (CRDF)?
Based on our DCF model, intrinsic value is $4.95, a +67.7% margin of safety versus $1.73.
What is Cardiff Oncology Inc's revenue?
TTM revenue is $593000.00.
Piotroski F-Score?
2/9 — weak financial health.
Altman Z-Score?
-2.58 — distress.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio198.31x
ROE-71.50%
Beta1.42
50D MA$1.74
200D MA$2.28
Shares out0.07B
Float0.07B
Short ratio—
Avg volume0.7M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—